Cleveland-Cliffs partnering with Nucor on potential bid for U.S. Steel, sources say

FAN Editor

A United Steelworkers sign is seen outside the Great Lakes Works United States Steel plant in River Rouge, Michigan U.S., September 16, 2024.

Rebecca Cook | Reuters

Cleveland Cliffs is partnering with rival Nucor in a potential bid for U.S. Steel, whose takeover by Japan’s Nippon Steel was just blocked by the White House earlier this month, sources tell CNBC’s David Faber.

Cleveland-Cliffs would purchase all of U.S. Steel for all cash and then sell off the Big River Steel subsidiary to Nucor, the sources said. U.S. Steel’s headquarters would remain in Pittsburgh under the deal.

The offer would be in the high $30s a share. Nippon had planned to buy U.S. Steel for $55 per share in a deal valued at more than $14 billion.

U.S. Steel shares jumped more than 7% in midmorning trading on Monday.

The White House over the weekend extended the deadline for Nippon to permanently end its pursuit of U.S. Steel until June, as the companies pursue a lawsuit in federal court against the decision to block the deal.

President Joe Biden’s decision to block the sale came after a review by the Committee on Foreign Investment in the United States, though he had made clear for months that he believes U.S. Steel should remain an American-owned company.

Biden cited national security concerns in his decision to block the deal, saying a strong domestic steel industry is critical for U.S. supply chains.

U.S. Steel CEO David Burritt has called on President-elect Donald Trump to reverse Biden’s decision to block the sale when he takes office later this month. Trump has also opposed Nippon’s acquisition of U.S. Steel.

This is a developing story. Please check back for updates.

Free America Network Articles

Leave a Reply

Next Post

Moderna stock plunges 20% after company lowers 2025 sales forecast by $1 billion

The Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024.  Adam Glanzman | Bloomberg | Getty Images Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and […]

You May Like